Key facts
- This page summarizes Anne Lesage's Form 4 filing for Pharvaris N.V. (PHVS).
- 11 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 01 May 2026, 19:30.
Anne Lesage - 29 Apr 2026 Form 4 Insider Report for Pharvaris N.V. (PHVS)
- Reporting relationship
- Chief Early Development
- Issuer ticker
- PHVS
- Reported as of
- 29 Apr 2026
- Net transaction value
- -$1,459,970
- SEC form
- 4
- Accepted by SEC
- 01 May 2026, 19:30:49 UTC
- Prior SEC filing
- 24 Apr 2026
- Next SEC filing
- 29 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anne Lesage filed Form 4 for Pharvaris N.V. (PHVS) on 01 May 2026.
Change
- Previous filing in this sequence was filed on 24 Apr 2026.
- Current net transaction value: -$1,459,970.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001973705
Primary reporting owner
Lesage Anne
- Relationship
- Chief Early Development
- Address
- 1 CRANBERRY HILL SUITE 400, LEXINGTON
- Signature
- /s/ Marnus Nel, Attorney-in-Fact for Anne Lesage
- Signature date
- 01 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,700
- Change %
- +6.6%
- Price
- $2.59*
- Shares after
- 60,150
- Date
- 29 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
transaction
Common Stock
Sale
- Transaction value
- $111,280
- Shares
- -3,700
- Change %
- -6.2%
- Price
- $30.08
- Shares after
- 56,450
- Date
- 29 Apr 2026
- Ownership
- Direct
- Footnotes
- F1, F2
PHVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,700
- Change %
- +6.6%
- Price
- $2.59*
- Shares after
- 60,150
- Date
- 30 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
transaction
Common Stock
Sale
- Transaction value
- $111,946
- Shares
- -3,700
- Change %
- -6.2%
- Price
- $30.26
- Shares after
- 56,450
- Date
- 30 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +18,000
- Change %
- +32%
- Price
- $8.05*
- Shares after
- 74,450
- Date
- 30 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
transaction
Common Stock
Sale
- Transaction value
- $544,604
- Shares
- -18,000
- Change %
- -24%
- Price
- $30.26
- Shares after
- 56,450
- Date
- 30 Apr 2026
- Ownership
- Direct
- Footnotes
- F1
PHVS
transaction
Common Stock
Sale
- Transaction value
- $111,229
- Shares
- -3,700
- Change %
- -2.4%
- Price
- $30.06
- Shares after
- 153,169
- Date
- 29 Apr 2026
- Ownership
- By GrayMatters Consulting BV
- Footnotes
- F2, F3, F4
PHVS
transaction
Common Stock
Sale
- Transaction value
- $580,909
- Shares
- -19,200
- Change %
- -13%
- Price
- $30.26
- Shares after
- 133,969
- Date
- 30 Apr 2026
- Ownership
- By GrayMatters Consulting BV
- Footnotes
- F3, F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHVS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,700
- Change %
- -22%
- Price
- $0.000000*
- Shares after
- 12,772
- Date
- 29 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,700
- Exercise price
- $2.59
- Footnotes
- F1, F6
PHVS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,700
- Change %
- -29%
- Price
- $0.000000*
- Shares after
- 9,072
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,700
- Exercise price
- $2.59
- Footnotes
- F1, F6
PHVS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -18,000
- Change %
- -18%
- Price
- $0.000000*
- Shares after
- 82,000
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,000
- Exercise price
- $8.05
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
This is a scheduled exercise and sale from 10b5-1 trading plan.
Footnote F2
The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F3
This is a scheduled sale from 10b5-1 trading plan.
Footnote F4
GrayMatters Consulting B.V., an entity controlled by Dr. Lesage
Footnote F5
The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Footnote F6
25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
Footnote F7
25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.